Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808773 | 0.93 | ADAM17 (0.41) | ADAM17TSHRALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL4808768 | 0.93 | ADAM17 (0.41) | ADAM17TSHRALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL4811142 | 0.90 | OPRK1 (0.40) | ADAM17SMN1; SMN2 | |
| SCHEMBL4807371 | 0.90 | KDM4E (0.46) | ADAM17ALDH1A1SMN1; SMN2CHRNA7 | |
| SCHEMBL4810012 | 0.88 | CHRNA7 (0.43) | TSHRALDH1A1SMN1; SMN2CHRNA7 | |
| SCHEMBL4817042 | 0.88 | ADAM17 (0.45) | ADAM17TSHRALDH1A1ALOX15SMN1; SMN2 | |
| SCHEMBL4816473 | 0.88 | TSHR (0.41) | TSHRCHRNA7HTR3EHTR3BHTR3A | |
| SCHEMBL4809852 | 0.88 | TRPM8 (0.38) | TSHRALDH1A1CHRNA7HTR3EHTR3B | |
| SCHEMBL4811198 | 0.87 | TDP1 (0.41) | ADAM17ALDH1A1SMN1; SMN2 | |
| SCHEMBL4813131 | 0.86 | BCHE (0.43) | ADAM17ALDH1A1SMN1; SMN2TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388103-B2 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2008-06-17 | — | — | US | disclosed |
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | US | disclosed |
| WO-2006045246-A1 | CYCLOPENTANE CARBOXYLATE COMPOUNDS, PROCESS AND INTERMEDIATES FOR PREPARING THE SAME AND USE THEREOF | CHINA PETROLEUM & CHEMICAL CORPORATION (CN) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094843-A1 | Cyclopentane carboxylate compounds, process and intermediates for preparing the same and use thereof | C5, C1S, AKR1C3 | ADAM17 2714/4885TSHR 4305/4885ALDH1A1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.